Posts

Biologics vs. JAK Inhibitors for Atopic Dermatitis: Which One Wins for Your Patient? A 2026 Practical Guide

2025: A Breakthrough Year for Chronic Urticaria - New FDA Approvals Reshaped Treatment

Revolutionizing Respiratory Care: How Type 2 Biologics Are Changing the Game for Severe Asthma and Beyond

New Targeted Systemic Therapies Are Revolutionizing Allergy Care

Tezepelumab in Real-World Danish Severe Asthma Study: Benefits Even After Biologic Switches

Tezepelumab vs. Dupilumab in Severe Asthma: Head-to-Head Real-World Data Shows No Clear Winner

Omalizumab Helps High-Risk Patients Tolerate Honeybee Venom Allergy Shots

Dupilumab-Induced Eosinophilia (DIBE) in CRSwNP Affected 48% of Patients

Why Some Chronic Hives Patients May Not Respond Well to Omalizumab: New Biopredictors Identified

Chronic Urticaria: Making Breakthroughs if Managing a Challenging Disease

Hope for Some Alpha-Gal Patients: In-home Graded Protocol

Are These New Biologics Game-Changers or Just More of the Same?

The Esophagus: Not Just a Tube, But a Smart Immune Organ

Artificial intelligence in Allergy and Immunology - JACI review

Staph Aureus on the Skin Associated With Severe Food Allergic Reactions Via a Cascade: IL-33, IL-3, IL-4

Predicting Outcomes in Common Variable Immunodeficiency (CVID)

New Risk Score Predicts Nasal Polyp Recurrence After Sinus Surgery for CRSwNP

Oral ITK Inhibitor Soquelitinib in Development for Atopic Dermatitis

Monoclonal Antibody Targeting OX40L (Amlitelimab) In Development for Atopic Dermatitis

EoE Pipeline Update: Dupilumab Leads, But Exciting Contenders Are Closing In